Health Care Knowledge

  Anakinra is an efficient medicine that is sold under the brand Kineret. It blocks the biological activity of interleukin, and it acts as immunosuppressive medicine. It is available in India, and you can easily   buy KINERET injections online   through various recognized and authorized platforms. Kineret can only be purchased with a prescription, and treatment should be started and supervised by a doctor who has experience in the diagnosis and treatment of the conditions for which it is used. Following are the recommended doses for KINERET: Rheumatoid Arthritis (RA) The recommended dose of Kineret for the treatment of patients with rheumatoid arthritis is 100 mg/day, which is administered daily by subcutaneous injection into the skin. The dose should be administered at approximately the same time every day. Physicians should consider a dose of 100 mg of  KINERET injection  administered every other day for rheumatoid arthritis for patients who have severe renal insufficiency or end-sta

Generic Name:   Tafasitamab Company:  Morphosis/Incyte Approval Status:  Approved Drug Class:  Targeted Therapy Medicines General Information: Monjuvi contains an active salt known,n as Tafasitamab. The medicinal product is an engineered antibody that is designed to bind to the CD19 protein on B-cells that progress in an uncontrolled way in leukemia and lymphoma. According to a study named L-MIND 55% of individuals with relapsed/refractory (RR) diffuse large B-cell lymphoma (DLBCL) who received Monjuvi in combination with Lenalidomide followed by Lenalidomide alone experienced remission, including 37 percent with complete responses (CR). The median time span of response was 21.7 months. Monjuvi 200 mg injection (tafasitamab-cxix) was initially approved in July 2020. Indication/Uses of Monjuvi: The medicine Monjuvi is a CD-19-directed monoclonal antibody approved by the FDA for the treatment of relapsed/refractory diffuse large B-cell lymphoma (RR DLBCL) in combination with a medicine

  Key Takeaways: TNBC accounts for approximately 10% to 15% of all existing breast cancers. The majority of cases of Triple-Negative Breast Cancer are diagnosed in women aged 51 to 60 years. Triple-Negative Breast Cancer more commonly affects African American and Hispanic women. Breast cancer linked with a BRCA-1/BRCA-2 mutation is often, but not always, triple negative. mTNBC and Other Types of Breast Cancer: Different types of breast cancer are grouped by whether or not the cancerous cells have certain protein-named receptors. Cancerous cells typically may have a couple of types of hormones (either estrogen or progesterone) or another receptor named HER2.  If cancerous cells have (or are +Ve for)these receptors, they can be treated with therapies that are mainly designed to target those receptors or that result in making fewer hormones. But metastatic triple-negative breast cancer cells are negative for estrogen receptors (ER), progesterone receptors (PR), and HER2, which typically

Retevmo ( selpercatinib ) is a kinase inhibitor recommended by healthcare professionals to treat patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, and locally advanced or solid metastatic tumors with a RET gene fusion.  Indications and Usage RET Fusion-Positive Non-Small Cell Lung Cancer Healthcare professionals recommend Selpercatinib for treating patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).  Non-small cell lung cancer is one of the common types of lung cancer. With this disease, cancer cells begin in your lung tissues. Non-small cell lung cancer grows slowly compared to small cell lung cancer — but it often spreads to other parts of your body by the time it's diagnosed.  RET-Mutant Medullary Thyroid Cancer   The medicine Retevmo (Selpercatinib) is used by healthcare providers to treat RET-Mutant Medullary Thyroid Cancer.

Indication and Usage The medicine Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate drug, which is used in the treatment of adults suffering from locally advanced or metastatic triple-negative breast (mTNBC) cancer, HR+/HER2- metastatic breast cancer, and locally advanced or metastatic urothelial cancer (mUC). It is used when it is not possible to remove cancer with surgery. Trodelvy  comes in the form of single-dose vials in 180 mg for intravenous infusion. Dosage Its dosage is based on body weight, and the recommended dosage is 10 mg/kg administered intravenously once weekly on the first day and eighth day of a repeating 21-day cycle. Administration First infusion: The drug is infused in the body for 3 hours, and during the infusion, the patient is observed for any adverse reaction caused by the infusion. After 30 minutes of infusion, observation should be done again to check for any post-infusion reaction. Subsequent Infusion: If the drug is tolerated in t